BRPI9708566A - Análogo de glp-2, análogo de peptìdeo glp-humano, peptìdeo, composição farmacêutica, uso de um análogo de glp-2, e, processo para identificar análogos intestinotróficos de glp-2. - Google Patents
Análogo de glp-2, análogo de peptìdeo glp-humano, peptìdeo, composição farmacêutica, uso de um análogo de glp-2, e, processo para identificar análogos intestinotróficos de glp-2.Info
- Publication number
- BRPI9708566A BRPI9708566A BR9708566-9A BRPI9708566A BRPI9708566A BR PI9708566 A BRPI9708566 A BR PI9708566A BR PI9708566 A BRPI9708566 A BR PI9708566A BR PI9708566 A BRPI9708566 A BR PI9708566A
- Authority
- BR
- Brazil
- Prior art keywords
- glp
- analog
- peptide
- analogs
- identifying
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 4
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 3
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000008467 tissue growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
"ANáLOGO DE GLP-2, ANáLOGO DE PEPTìDEO GLP-2 HUMANO, PEPTìDEO, COMPOSIçãO FARMACêUTICA, USO DE UM ANáLOGO DE GLP-2, E, PROCESSO PARA IDENTIFICAR ANáLOGOS INTESTINOTRóPICOS DE GLP-2". Análogos de peptídeo semelhante a glucagona 2, um produto de expressão de gene de glucagona, foram indentificados como fatores de crescimento de tecido intestinal. Sua formulação como uso farmacêutico e terapêutico no tratamento de distúrbios do intestino delgado é descrita.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63127396A | 1996-04-12 | 1996-04-12 | |
| PCT/CA1997/000252 WO1997039031A1 (en) | 1996-04-12 | 1997-04-11 | Glucagon-like peptide-2 analogs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI9708566A true BRPI9708566A (pt) | 2000-01-04 |
| BR9708566B1 BR9708566B1 (pt) | 2012-09-04 |
| BRPI9708566B8 BRPI9708566B8 (pt) | 2022-01-18 |
Family
ID=24530501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9708566A BRPI9708566B8 (pt) | 1996-04-12 | 1997-04-11 | análogo de glp-2 de mamífero, e, composição farmacêutica. |
Country Status (16)
| Country | Link |
|---|---|
| EP (5) | EP2275438A1 (pt) |
| JP (3) | JP4148994B2 (pt) |
| CN (1) | CN1268640C (pt) |
| AT (2) | ATE227309T1 (pt) |
| AU (1) | AU733857B2 (pt) |
| BR (1) | BRPI9708566B8 (pt) |
| CA (1) | CA2251576C (pt) |
| DE (2) | DE69716905T2 (pt) |
| DK (2) | DK0906338T3 (pt) |
| ES (2) | ES2188929T3 (pt) |
| FR (1) | FR13C0013I2 (pt) |
| HK (1) | HK1050204B (pt) |
| LU (1) | LU92153I2 (pt) |
| NZ (1) | NZ332281A (pt) |
| PT (2) | PT906338E (pt) |
| WO (1) | WO1997039031A1 (pt) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| EP2275438A1 (en) | 1996-04-12 | 2011-01-19 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
| US5952301A (en) * | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| ATE253375T1 (de) * | 1997-05-16 | 2003-11-15 | Ontario Inc 1149336 | Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes |
| AU2712899A (en) * | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates |
| AU7421598A (en) * | 1998-05-11 | 1999-11-29 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| GB9930882D0 (en) * | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| PT1326630E (pt) | 2000-09-18 | 2008-09-02 | Sanos Bioscience As | Utilização de péptidos glp-2 |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
| DE602004031927D1 (de) | 2003-02-04 | 2011-05-05 | Novo Nordisk As | Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung |
| DE602004022177D1 (de) * | 2003-08-21 | 2009-09-03 | Novo Nordisk As | Reinigung glucagonähnlicher peptide |
| EP2033662B1 (en) | 2004-01-21 | 2012-10-17 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| DK1809318T3 (da) | 2004-11-01 | 2013-09-08 | Nps Pharma Inc | Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet |
| DE602006020123D1 (de) | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| CN100418983C (zh) * | 2005-05-11 | 2008-09-17 | 中国药科大学 | 人胰高血糖素相关肽-2类似物 |
| AU2007319066B2 (en) * | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| CN101824087A (zh) * | 2009-03-05 | 2010-09-08 | 连云港恒邦医药科技有限公司 | 胰高血糖素样肽-2类似物及其制备方法和用途 |
| EP2311486A1 (en) * | 2009-10-07 | 2011-04-20 | Nestec S.A. | GLP-2 for use in intestine and muscle recovery |
| EP2314616A1 (en) * | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
| CA2778890A1 (en) * | 2009-10-30 | 2011-05-05 | Otsuka Chemical Co., Ltd. | Glycosylated form of antigenic glp-1 analogue |
| CA2797033C (en) | 2010-04-22 | 2021-10-19 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| EP2569001A4 (en) * | 2010-05-11 | 2014-06-25 | Nps Pharma Inc | PROCEDURE FOR TREATING OR PREVENTING KIDNEY OR REFUSE FUNCTIONS |
| US20140249090A1 (en) | 2011-04-01 | 2014-09-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. | Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders |
| CN102924589B (zh) * | 2011-08-11 | 2016-08-24 | 中肽生化有限公司 | 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途 |
| EA028929B1 (ru) | 2012-05-03 | 2018-01-31 | Зилэнд Фарма А/С | Аналоги глюкагоноподобного пептида-2 (glp-2) |
| CN103159848B (zh) * | 2013-01-06 | 2015-11-25 | 中国人民解放军第四军医大学 | 人胰高血糖素样肽-2二串体蛋白及其制备方法 |
| WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
| US10774127B2 (en) * | 2016-10-12 | 2020-09-15 | University Of Copenhagen | Peptide dual agonists of GIPR and GLP2R |
| KR102502040B1 (ko) | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | 아실화 glp-1/glp-2 이중 효능제 |
| IL271245B2 (en) | 2017-06-16 | 2023-10-01 | Zealand Pharma As | Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2 |
| WO2019086559A1 (fr) | 2017-10-31 | 2019-05-09 | Adocia | Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
| EP3628683A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| EP3628682A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| US20200254065A1 (en) | 2019-02-11 | 2020-08-13 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
| SG11202111312UA (en) | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| US20230110689A1 (en) | 2020-03-30 | 2023-04-13 | Zealand Pharma A/S | Agonist combination |
| US20250304643A1 (en) * | 2021-12-17 | 2025-10-02 | Bainan Biotech Aps | Peptide dual agonists of gipr and glp2r |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5186117A (en) | 1975-01-27 | 1976-07-28 | Tanabe Seiyaku Co | Johoseibiryushiseizainoseiho |
| GB1575343A (en) | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
| US4529561A (en) | 1978-03-24 | 1985-07-16 | The Regents Of The University Of California | Method for producing liposomes in selected size range |
| GB2046092B (en) | 1979-03-05 | 1983-11-02 | Toyama Chemical Co Ltd | Pharmaceutical composition containing a lysophospholid and a phospholipid |
| US4452747A (en) | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
| US4725442A (en) | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
| US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
| US4921706A (en) | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US5009956A (en) | 1987-02-24 | 1991-04-23 | Univ Minnesota | Phospholipase A2-resistant liposomes |
| US4927637A (en) | 1989-01-17 | 1990-05-22 | Liposome Technology, Inc. | Liposome extrusion method |
| US4944948A (en) | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
| JP2961045B2 (ja) | 1993-02-24 | 1999-10-12 | 日清製粉株式会社 | 腸管粘膜増強促進剤 |
| CA2137206A1 (en) | 1993-12-09 | 1995-06-10 | John A. Galloway | Glucagon-like insulinotropic peptides, compositions and methods |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| EP1975177B1 (en) | 1996-03-01 | 2011-04-13 | Novo Nordisk A/S | An appetite-suppressing peptide, its compositions and use |
| EP2275438A1 (en) | 1996-04-12 | 2011-01-19 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
| US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
| WO2002066062A2 (en) | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
-
1997
- 1997-04-11 EP EP10012937A patent/EP2275438A1/en not_active Withdrawn
- 1997-04-11 AU AU25002/97A patent/AU733857B2/en not_active Expired
- 1997-04-11 EP EP97916280A patent/EP0906338B1/en not_active Expired - Lifetime
- 1997-04-11 BR BRPI9708566A patent/BRPI9708566B8/pt active IP Right Grant
- 1997-04-11 EP EP08154386A patent/EP2009024A1/en not_active Withdrawn
- 1997-04-11 ES ES97916280T patent/ES2188929T3/es not_active Expired - Lifetime
- 1997-04-11 CN CNB971953317A patent/CN1268640C/zh not_active Expired - Lifetime
- 1997-04-11 EP EP01129072A patent/EP1231219B1/en not_active Expired - Lifetime
- 1997-04-11 DE DE69716905T patent/DE69716905T2/de not_active Expired - Lifetime
- 1997-04-11 EP EP10163303.0A patent/EP2218734B1/en not_active Expired - Lifetime
- 1997-04-11 PT PT97916280T patent/PT906338E/pt unknown
- 1997-04-11 AT AT97916280T patent/ATE227309T1/de active
- 1997-04-11 WO PCT/CA1997/000252 patent/WO1997039031A1/en not_active Ceased
- 1997-04-11 NZ NZ332281A patent/NZ332281A/xx not_active IP Right Cessation
- 1997-04-11 DK DK97916280T patent/DK0906338T3/da active
- 1997-04-11 JP JP53660897A patent/JP4148994B2/ja not_active Expired - Lifetime
- 1997-04-11 DK DK01129072.3T patent/DK1231219T3/da active
- 1997-04-11 AT AT01129072T patent/ATE478892T1/de active
- 1997-04-11 CA CA2251576A patent/CA2251576C/en not_active Expired - Lifetime
- 1997-04-11 DE DE60142885T patent/DE60142885D1/de not_active Expired - Lifetime
- 1997-04-11 ES ES01129072T patent/ES2351661T3/es not_active Expired - Lifetime
-
2001
- 2001-12-07 PT PT01129072T patent/PT1231219E/pt unknown
-
2003
- 2003-02-07 HK HK03100905.1A patent/HK1050204B/en not_active IP Right Cessation
-
2007
- 2007-04-24 JP JP2007114302A patent/JP4149497B2/ja not_active Expired - Lifetime
-
2008
- 2008-02-07 JP JP2008027918A patent/JP5019466B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-19 LU LU92153C patent/LU92153I2/fr unknown
- 2013-02-22 FR FR13C0013C patent/FR13C0013I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2218734A3 (en) | Glucagon-like peptide-2 analogs | |
| CY2615B2 (en) | Glucagon-like peptide-2 and its therapeutic use | |
| EP0552256A4 (pt) | ||
| RU94027680A (ru) | Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы | |
| DE69840909D1 (de) | Analoge von kokain | |
| ES2191329T3 (es) | Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares. | |
| ATE213164T1 (de) | Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids | |
| BR9106114A (pt) | Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica | |
| BR9506847A (pt) | Composto composição farmacêutica uso de um composto processo para o tratamento da dor | |
| ES2088959T3 (es) | 11-beta-aril-4-estreno, procedimiento para su preparacion y aplicacion como medicamento. | |
| MX9805705A (es) | Compuestos biaromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones. | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| DE69200711D1 (de) | Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung. | |
| BR9811755A (pt) | Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica | |
| MX9707668A (es) | Compuestos biarilicos heterociclicos, composiciones farmaceuticas y cosmeticas que los contienen y uso de las mismas. | |
| RU95106680A (ru) | Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции | |
| MX9708803A (es) | Compuestos biaromaticos de propinilo o dienilo. | |
| BR9915951A (pt) | Processo para preparação de uma composição farmacêutica para uso como um medicamento antiarritmias com um bloqueio beta adrenérgico controlado, composição farmacêutica, preparação oral e parenteral para tratamento de doenças cardìacas em mamìferos, e, método de tratamento para as mesmas | |
| ES2039196T3 (es) | Procedimiento para preparar 4-(1,2,5,6-tetrahidro-1-alquil-3-piridinil)-2-tiazolaminas y 4-(hexahidro-1-alquil-3-piridinil)-2-tiazolaminas. | |
| BR9708297A (pt) | Compostos composição farmacéutica cosmposição e uso de uma composição cosmética | |
| TW374085B (en) | Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use | |
| ATE136465T1 (de) | Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis | |
| NZ303993A (en) | Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders | |
| ATE245998T1 (de) | Somatostatin agoniste zur reduzierung von körpergewicht | |
| BG103905A (en) | New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine |